噻托溴铵联合舒利迭治疗稳定器COPD的临床疗效及安全性分析

Analysis of clinical efficacy and safety of tiotropium combined with Seretide treatment stabilizer COPD

目的探讨噻托溴铵联合舒利迭治疗COPD的临床疗效。方法选取本院2016年1月~2017年6月收治的120例COPD患者,随机分为观察组与对照组,观察组采用噻托溴铵联合舒利迭治疗,对照组单用舒利迭治疗,对比分析两组患者临床疗效。结果两组患者治疗前FEV_1、FVC、FEV_1/FVC、FEV_1预计值肺功能指标差异无统计学意义;治疗后,观察组FEV_1、FVC、FEV_1/FVC、FEV_1肺功能指标明显优于治疗前,差异具有统计学意义(P<0.05);治疗后对照组FEV_1、FVC、FEV_1/FVC、FEV_1肺功能指标明显优于治疗前,差异具有统计学意义(P<0.05);治疗后观察组FEV_1、FVC、FEV_1/FVC、FEV_1预计值肺功能指标明显优于对照组,差异具有统计学意义(P<0.05)。治疗前,两组患者TXB2、NO、ET-1、SICAM指标差异无统计学意义,治疗后观察组TXB2、NO、ET-1、SICAM指标上明显优于对照组,差异具有统计学意义(P<0.05)。对照组有恶心呕吐3例,口干咽喉不适3例,不良反应发生率10.0%;观察组恶心呕吐4例,口干咽喉不适共3例,不良反应发生率为11.7%,两组患者不良反应发生率差异无统计学意义。结论采用噻托溴铵联合舒利迭治疗COPD能明显改善患者肺功能,能明显改善老年COPD患者血管内皮细胞功能,可能减少心血管事件的发生,两种药物治疗不良反应较少,安全性高。

Objective To investigate the clinical efficacy of tiotropium combined with Seretide in the treatment of COPD.Methods 120 cases of COPD patients in our hospital from January 2016 to June 2017,were randomly divided into observation group and control group,the observation group with tiotropium combined with Seretide treatment,control group was treated with Seretide treatment,comparative analysis of two groups the clinical curative effect.Results Two groups of patients before treatment,FEV1,FVC,FEV1/FVC,FEV1 predicted lung function index had no significant difference,after treatment,the observation group FEV1,FVC,FEV1/FVC,pulmonary function index FEV1 were significantly better than before treatment,the difference was statistically significant(P<0.05),the control group after treatment FEV1,FVC,FEV1/FVC,FEV1,pulmonary function indexes were significantly better than before treatment,the difference was statistically significant(P<0.05),after treatment,the observation group FEV1,FVC,FEV1/FVC,FEV1,pulmonary function index was significantly better than the expected value the control group,the difference was statistically significant(P<0.05).Before treatment,no significant difference between the two groups of TXB2,NO,ET-1,SICAM index,the observation group after treatment TXB2,NO,ET-1,SICAM index was significantly better than the control group,the difference was statistically significant(P<0.05),control group had 3 cases of nausea and vomiting dry mouth,throat discomfort in 3 cases,the incidence of adverse reactions was 10.0%,the observation group of 4 cases of nausea and vomiting,dry mouth and throat discomfort in 3 cases,the incidence rate of adverse reaction was 11.7%,two groups of patients with adverse reaction rate was has no significantly difference.Conclusion Using tiotropium combined with Seretide treatment can obviously improve the pulmonary COPD function of patients,can significantly improve the function of vascular endothelial cells in patients with senile COPD,may reduce the incidence of cardiovascular events,two kinds of drug treatment with less adverse reaction,high safety.